GSK shares fell 4.7% to 1,834p in London on Wednesday morning after sales of its Shingrix shingles vaccine and Arexvy RSV vaccine missed forecasts. That overshadowed a third quarter in which core operating profit rose 5% at constant exchange rates to £3.08bn, well ahead of expectations.
Most of the numbers beat what analysts had pencilled in. Turnover of £8.89bn was 0.6% above a company-compiled consensus of £8.84bn, and core earnings per share of 54.6p compared with 50.4p expected, according to AJ Bell. But the market focused on vaccines, the one large division that went backwards.
| Measure | Q3 2026 | Consensus |
|---|---|---|
| Turnover | £8.89bn | £8.84bn |
| Core operating profit | £3.08bn | £2.93bn |
| Core EPS | 54.6p | 50.4p |
| Specialty Medicines | £3.88bn | £3.85bn |
| Vaccines | £2.58bn | £2.62bn |
| General Medicines | £2.43bn | £2.37bn |
Vaccines were the weak spot
Vaccine sales fell 2% at constant exchange rates to £2.6bn. Shingrix, GSK's biggest vaccine, fell 5% to £0.8bn and came in about 8% below forecasts. Arexvy fell 24% to £0.2bn, roughly 16% short of expectations. GSK's results statement did not give a reason for either decline.
Meningitis vaccines were the bright spot, growing 12% to £0.6bn. GSK also won Japanese approval for a pre-filled syringe version of Shingrix.
Label
- -4.7% GSK shares, Wednesday morning
- -5% Shingrix sales, to £0.8bn
- -24% Arexvy sales, to £0.2bn

Specialty medicines carried the quarter
Specialty Medicines grew 15% to £3.9bn. HIV medicines, sold through ViiV Healthcare, rose 10% to £2.1bn. Respiratory, immunology and inflammation grew 21% to £1.1bn, and oncology grew 23% to £0.6bn. General Medicines was stable at £2.4bn, with the Trelegy inhaler up 8% to £0.8bn.
Profit benefited from a better product and regional mix and from royalty income of £258m, against £224m expected, while selling and administrative costs were lower than forecast. JPMorgan analysts noted that the earnings beat was proportionally much larger than the sales beat, reflecting a higher gross margin, more royalty income and lower overheads.
Reported figures were weaker. Total operating profit fell 16% at constant rates to £2.13bn and total EPS fell 21% to 38.5p, mainly because of £328m of restructuring charges for GSK's Accelerate Growth programme. Cash generated from operations rose 24% to £3.12bn, and free cash flow was £2.1bn.
Guidance held, not raised
Chief executive Luke Miels said: "GSK has delivered another strong quarter." The company kept its 2026 forecasts at constant exchange rates rather than raising them:
GSK's 2026 guidance
- Turnover growth of 3% to 5%, now expected towards the upper half
- Core operating profit growth of 7% to 9%, towards the upper half
- Core EPS growth of 7% to 9%, towards the lower half
- A full-year dividend of 70p expected, with 17p declared for the third quarter
GSK also said it remains on track for more than £40bn of sales in 2031, and that it expects its operating margin to be stable or improving while its HIV drug dolutegravir loses patent protection between 2028 and 2030.
What investors watch next
With the vaccine business shrinking, the investment case leans more heavily on the pipeline. GSK listed US and Japanese approvals for Hibsago in chronic hepatitis B, a US approval for Jemperli in a form of rectal cancer and positive registrational data for Jideytro in first-line lung cancer. It has started a phase III trial of an mRNA seasonal flu vaccine, and 18 of the 22 phase III starts planned for 2026 are already under way.
Before the results, GSK shares closed at £18.94 on 23 October, up 1.69% that week and about 2% above their level at the end of August. Wednesday's fall takes them back below that August level, and the next test is whether Shingrix and Arexvy sales stabilise in the fourth quarter.
Sources
- GSK: GSK delivers strong Q3 performance and continued momentum
- AJ Bell: GSK beats expectations but Shingrix and Arexvy miss weighs on Vaccines
- BMK News market data (delayed exchange data)








